Skip to main content

Autolus Therapeutics plc

AUTL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001730463

In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Autolus Therapeutics plc changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of AUTL: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders89184−4
Shares139.3M26.9K134.4M−4.88M (−3.5%)
Value$277.1M$53.5K$184.4M−$92.6M (−33.4%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (9)

Institutions that held Autolus Therapeutics plc at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to AUTL in Q1 2026
InstitutionSharesValue% of portfolio
Balyasny Asset Management LLC971,691$1.34M0.00%
Marex Group plc542,857$749.1K0.01%
Millennium Management LLC204,728$282.5K0.00%
Aquatic Capital Management LLC114,398$157.9K0.00%
Warren Averett Asset Management, LLC26,870$37.1K0.00%
Apollon Wealth Management, LLC14,003$19.3K0.00%
Claro Advisors LLC12,500$17.3K0.00%
QRG Capital Management, Inc.10,925$15.1K0.00%
Barclays PLC8,074$11.1K0.00%

Sold out (13)

Institutions that held Autolus Therapeutics plc at the end of Q4 2025 and filed for Q1 2026 without it.

Not filed for Q1 2026 yet (1)

Institutions that held Autolus Therapeutics plc at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AUTL in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Forefront Wealth Management Inc.26,870$53.5K